Jazz Other Operating Expenses vs Ebit Analysis
JAZZ Stock | USD 110.49 0.75 0.68% |
Jazz Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jazz Pharmaceuticals PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jazz Pharmaceuticals PLC is a good investment. Please check the relationship between Jazz Pharmaceuticals Other Operating Expenses and its Ebit accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Other Operating Expenses vs Ebit
Other Operating Expenses vs Ebit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jazz Pharmaceuticals PLC Other Operating Expenses account and Ebit. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Jazz Pharmaceuticals' Other Operating Expenses and Ebit is 0.45. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Ebit in the same time period over historical financial statements of Jazz Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Jazz Pharmaceuticals' Other Operating Expenses and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Jazz Pharmaceuticals PLC are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Other Operating Expenses i.e., Jazz Pharmaceuticals' Other Operating Expenses and Ebit go up and down completely randomly.
Correlation Coefficient | 0.45 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Jazz Pharmaceuticals PLC. It is also known as Jazz Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Ebit
Most indicators from Jazz Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jazz Pharmaceuticals PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Selling General Administrative is likely to rise to about 1.4 B in 2024, despite the fact that Tax Provision is likely to grow to (177.5 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 2.7B | 3.1B | 2.8B | 2.9B | Total Revenue | 3.1B | 3.7B | 3.8B | 4.0B |
Jazz Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Jazz Pharmaceuticals Account Relationship Matchups
Jazz Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 57.6M | 56.5M | 59.7M | 62.5M | 72.1M | 51.5M | |
Total Assets | 5.5B | 6.5B | 12.3B | 10.8B | 11.4B | 12.0B | |
Short Long Term Debt Total | 1.8B | 2.2B | 6.1B | 5.8B | 5.8B | 6.1B | |
Other Current Liab | 278.8M | 377.9M | 675.9M | 811.0M | 774.5M | 813.2M | |
Total Current Liabilities | 364.5M | 653.7M | 809.3M | 933.2M | 1.5B | 1.6B | |
Total Stockholder Equity | 3.1B | 3.7B | 4.0B | 3.1B | 3.7B | 3.9B | |
Other Liab | 337.7M | 233.9M | 1.4B | 1.0B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 270.9M | 257.1M | 343.4M | 301.4M | 235.0M | 119.6M | |
Net Debt | 1.1B | 1.2B | 5.5B | 4.9B | 4.6B | 4.8B | |
Retained Earnings | 1.1B | 1.2B | 830.2M | 733.6M | 878.7M | 922.6M | |
Accounts Payable | 47.5M | 26.9M | 100.3M | 90.8M | 102.8M | 107.9M | |
Cash | 637.3M | 1.1B | 591.4M | 881.5M | 1.2B | 1.3B | |
Non Current Assets Total | 3.9B | 3.7B | 9.7B | 8.2B | 8.1B | 8.5B | |
Non Currrent Assets Other | 47.9M | 25.7M | 40.8M | 58.9M | 240.7M | 252.8M | |
Other Assets | 272.2M | 415.0M | 363.9M | 435.1M | 500.4M | 525.4M | |
Long Term Debt | 1.6B | 1.8B | 6.0B | 5.7B | 5.1B | 5.4B | |
Cash And Short Term Investments | 1.1B | 2.1B | 591.4M | 881.5M | 1.6B | 1.7B | |
Net Receivables | 356.0M | 396.5M | 563.4M | 651.5M | 705.8M | 741.1M | |
Good Will | 920.0M | 958.3M | 1.8B | 1.7B | 1.8B | 1.8B | |
Short Term Investments | 515M | 440M | 1.1B | 30M | 420M | 441M | |
Liabilities And Stockholders Equity | 5.5B | 6.5B | 12.3B | 10.8B | 11.4B | 12.0B | |
Non Current Liabilities Total | 2.1B | 2.2B | 7.5B | 6.8B | 6.1B | 6.4B | |
Inventory | 78.6M | 95.4M | 1.1B | 714.1M | 597.0M | 626.9M | |
Other Current Assets | 78.9M | 152.5M | 252.4M | 267.2M | 334.8M | 351.5M | |
Other Stockholder Equity | 2.3B | 2.6B | 3.5B | 3.5B | 3.7B | 3.9B | |
Total Liab | 2.4B | 2.9B | 8.3B | 7.7B | 7.7B | 8.0B | |
Property Plant And Equipment Gross | 270.9M | 257.1M | 343.4M | 301.4M | 368.3M | 386.8M | |
Total Current Assets | 1.6B | 2.8B | 2.6B | 2.6B | 3.3B | 3.4B | |
Accumulated Other Comprehensive Income | (223.4M) | (134.4M) | (400.4M) | (1.1B) | (841.7M) | (799.6M) | |
Intangible Assets | 2.4B | 2.2B | 7.2B | 5.8B | 5.4B | 5.7B | |
Property Plant Equipment | 270.9M | 127.9M | 343.4M | 301.4M | 346.6M | 363.9M | |
Current Deferred Revenue | 4.7M | 2.5M | 2.1M | 463K | 35.1M | 36.8M | |
Net Tangible Assets | (250.0M) | 648.7M | (5.0B) | (4.3B) | (3.9B) | (3.7B) | |
Capital Surpluse | 2.3B | 2.6B | 3.5B | 3.5B | 4.0B | 2.2B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.757 | Earnings Share 4.83 | Revenue Per Share 60.956 | Quarterly Revenue Growth 0.01 | Return On Assets 0.0407 |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.